Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses

Q: What does this research mean for the field?

Accurate assessment of 177Lu-PSMA-617 acquisition costs is necessary for valid cost-effectiveness analyses of radiopharmaceutical therapies in the U.S. healthcare system. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Kyle Flannery; Paul F. Cavanaugh; Kevin Steele

doi:10.2967/jnumed.126.272999

September 3, 2026Journal of Nuclear MedicineOpen Access

Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses

View Full Paper

Ask AI

Bookmark

Share

Key Points

To reassess acquisition costs of 177Lu-PSMA-617 and determine their impact on cost-effectiveness comparisons against cabazitaxel in the U.S. health care setting.
Reviewed acquisition cost inputs and methodology used in published cost-effectiveness evaluations comparing 177Lu-PSMA-617 and cabazitaxel.
Evaluated the sensitivity of economic outcomes to pricing assumptions from a U.S. health care perspective.
Identifies that baseline drug acquisition pricing heavily dictates relative cost-effectiveness ratios between radioligand therapy and taxane chemotherapy.
Demonstrates that adjusting acquisition pricing substantially shifts economic favorability thresholds for radiopharmaceuticals in advanced prostate cancer.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Economic evaluation reports modified 177Lu-PSMA-617 drug costs versus cabazitaxel in prostate cancer, highlighting major implications for U.S. radiopharmaceutical cost-effectiveness.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Flannery et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4346b95aff0620ebace https://doi.org/10.2967/jnumed.126.272999

View Full Paper

Ask AI

Bookmark

Share

Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Reassessing 177 Lu-PSMA-617 Acquisition Costs: Implications for U.S. Radiopharmaceutical Therapy Cost-Effectiveness Analyses

Key Points

No abstract yet

Implication

Discussion

Cite This Study

Keep reading

Keep reading